Plain-English translation of NCT06888921 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which is designed to help your immune system fight ovarian cancer that has come back after previous treatment. In the first part of the study, participants will be randomly assigned to receive either or a placebo (a look-alike substance with no active drug) — there's about a 2 in 3 chance you'd receive the actual medication. Later parts of the study will test whether combining this medication with other cancer drugs works even better.
Ovarian cancer that returns after chemotherapy is very difficult to treat, and current standard options (like bevacizumab or PARP inhibitors) don't work for everyone or stop working over time. This trial is exploring whether this medication, which works by activating your immune system in a new way, could offer another effective option for people in this situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to receive either the medication or a placebo through an injection or infusion. You'll have regular clinic visits to receive your doses and have your blood tested and imaging done to see how you're responding. The study involves comparing how well the medication works compared to placebo in slowing or stopping your cancer's return, and doctors will carefully monitor you for any side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States